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Introduction: Empiric antimicrobial selection for critical care infections must balance the need for timely adequate
coverage with the resistance pressure exerted by broadspectrum agents. We estimated the potential of weighted
incidence syndromic combination antibiograms (WISCAs) to improve time to adequate coverage for critical care
infections. In contrast to traditional antibiograms, WISCAs display the likelihood of coverage for a specific infectious
syndrome (rather than individual pathogens), and also take into account the potential for poly-microbial infections
and the use of multi-drug regimens.
Methods: Cases of ventilator-associated pneumonia (VAP) and catheter-related bloodstream infection (CRBSI) were
identified over three years using stringent surveillance criteria. Based on the susceptibility profile of the culprit
pathogens, we calculated the WISCA percentages of infections that would have been adequately covered by
common antimicrobial(s). We then computed the excess percentage coverage offered by WISCA regimens
compared to the actual antimicrobials administered to patients by 12 h, 24 h, and 48 h from culture collection.
Results: Among 163 patients with critical care infection, standard practice only resulted in adequate coverage of
35% of patients by 12 h, 52% by 24 h, and 75% by 48 h. No WISCA mono-therapy regimen offered greater than
85% adequate overall coverage for VAP and CRBSI. A wide range of dual therapy regimens would have conferred
greater than 90% adequate coverage, with excess coverage estimated to be as high as +56%, +42% and +18%
at 12 h, 24 h and 48 h, respectively. We did not detect a decrease in mortality associated with early adequate
treatment, and so could not estimate potential downstream benefits.
Conclusions: WISCA-derived empiric antimicrobial regimens can be calculated for patients with intensive care unit
(ICU)-acquired infections, and have the potential to reduce time to adequate treatment. Prospective research must
confirm whether implementation of WISCA prescribing aids facilitate timely adequate treatment and improved
ICU outcomes.Introduction
Several studies highlight that early provision of adequate
antibiotics improves survival outcomes among critically
ill patients with infection [1-3]. To ensure adequate anti-
microbial treatment, clinicians often prescribe broad-
spectrum empiric antibiotics while awaiting microbiology
culture and susceptibility results that will enable tailoring* Correspondence: nick.daneman@sunnybrook.ca
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reproduction in any medium, provided the orthe treatment regimen to the identified pathogen(s). Al-
though early broad-spectrum treatment helps ensure ef-
fective treatment of infections, overuse of broad-spectrum
antibiotics is driving antibiotic resistance [4]. A rise in
multi-drug resistant bacteria is limiting available thera-
peutic options for infections in the ICU, and further redu-
cing the likelihood that empiric treatment selections will
offer adequate coverage for common ICU pathogens.
To balance the needs of adequate drug therapy with
antimicrobial stewardship, Hebert et al. proposed the use
of a novel weighted-incidence syndromic combinationtral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sions [5]. Traditional antibiograms display the percentage
susceptibility of each common bacterial pathogen to each
common antimicrobial agent, but this does not help cli-
nicians select an empiric antimicrobial regimen prior to
identification of the culprit pathogen. In contrast, the
WISCA displays the likelihood of adequate coverage for a
specific infectious syndrome, taking into account the local
weighted incidence of pathogens causing that syndrome,
as well as the potential for poly-microbial infections and
multi-drug regimens [5]. Hebert et al. demonstrated the
potential of the WISCA to be more effective than stan-
dard antibiograms as an antibiotic-prescribing decision
aid for patients with urinary tract infections and intra-
abdominal infections [5].
The objectives of this study were to demonstrate the
generation of a WISCA for critical care infections (venti-
lator-associated pneumonia (VAP) and catheter-related
bloodstream infection (CRBSI)), to estimate the potential
improvement in time to adequate empiric coverage of
these infections as compared to current ICU practice if
WISCAs had been used, and then to estimate the poten-
tial downstream improvements in clinical outcomes for
these critically ill patients.
Materials and methods
Study overview and setting
A retrospective cohort study was conducted of all eligi-
ble adults diagnosed with VAP or CRBSI after admission
to the ICU from May 2010 to May 2013 at Sunnybrook
Health Sciences Centre (SHSC), a 700-bed university-
affiliated tertiary-care hospital in Toronto, Ontario,
Canada. SHSC Research Ethics Board (REB) approval was
obtained for the study; the REB waived the need for in-
formed consent, given the retrospective study design and
lack of potential harms to patients. Multiple infection epi-
sodes could occur for the same patient within the study
interval.
VAP and CRBSI case definitions
The clinical syndromes were identified by active infec-
tion control surveillance over the study period, accord-
ing to stringent case definitions as part of a mandatory
reporting program to the Ontario Ministry of Health
and Long-Term Care Critical Care Secretariat [6].
VAP was defined as a respiratory infection acquired by
a patient after being on intermittent or continuous me-
chanical ventilation through a tracheostomy or endo-
tracheal tube for at least 48 h that required antibiotic
treatment. The patient must have had evidence of a
new, worsening or persistent chest x-ray consolidation
or cavitation compatible with pneumonia, associated
with either white blood cell count <4,000 or >12,000,
or temperature <36°C or >38°C. In addition, the casedefinition required: a) new onset of purulent sputum,
or change in sputum character, or increase in respiratory
secretions, or increase in suctioning requirements; and b)
worsening gas exchange (for example, increasing oxygen
needs or minute ventilation, or a worsening arterial oxy-
gen tension/fraction of inspired oxygen (PaO2/FiO2) ratio)
[6]. Culture-negative episodes of VAP were excluded from
analysis, because by definition we would be unable to de-
termine adequacy of antibiotic treatment.
CRBSI was defined as one or more positive blood cul-
tures yielding a recognized pathogen or multiple positive
blood cultures yielding a potential skin organism (for
example, Bacillus spp., coagulase-negative Staphylococci,
Micrococcus spp., Corynebacterium spp., or Propionibac-
terium spp.) acquired by the patient after catheter in-
sertion for ≥48 h with no other identifiable source, along
with one or more of fever ≥38°C, chills or hypotension [6].
By definition, all episodes of CRBSI are culture-positive,
and so adequacy of antibiotic treatment could be deter-
mined for all cases.Microbiologic methods
In the SHSC microbiology laboratory, respiratory speci-
mens from tracheal aspirates, and bronchoscopic speci-
mens were plated on blood, bacitracin chocolate and
MaConkey agar, and organism identification and suscepti-
bilty were reported if there was moderate to heavy growth
on culture, or growth above normal flora, or regardless of
quantity on culture if the same pathogen was also predom-
inant in the Gram stain. Blood cultures were performed
using the BACTEC 9240 blood culture system (Becton
Dickinson Diagnostic Instruments Systems, Franklin Lakes,
New Jersey, USA) [7] in accordance with Clinical Laboratory
Standards Institute guidelines.Definition of adequate empiric antibiotic treatment
The time to initiation of adequate empiric antibiotic the-
rapy for an infection was defined as the time from cul-
ture collection to first administration of an antibiotic to
which isolated pathogen(s) were all susceptible. Access
was obtained to all antimicrobial susceptibility testing
data performed by the laboratory, including those that
were suppressed from reporting to clinicians. Intermedi-
ate susceptibility to an antibiotic was considered equiva-
lent to resistance to that antibiotic. Where test results
were not available for a specific antibiotic, antibiotic sus-
ceptibility was imputed when possible based on litera-
ture and expert review. For example, all Gram-negative
bacilli were deemed resistant to vancomycin even though
no testing would have been performed for this agent; simi-
larly, all Streptococci were considered susceptible to line-
zolid, even if testing was not undertaken.
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Study data were extracted from the Critical Care Infor-
mation System (CCIS) and Stewardship Program Integra-
ted Resource Information Technology (SPIRIT) databases,
and from chart review. The CCIS contains information re-
garding VAP and CRBSI diagnoses, as well as multi organ
dysfunction scores (MODS) as a marker of severity of ill-
ness on admission; [6] the SPIRIT database contains infor-
mation regarding all culture and susceptibility data and
antibiotic therapies; [8] chart review was conducted for
other important covariates. We abstracted data regarding
patient demographics (including age, gender, and co-
morbidities), risk factors for antibiotic resistance (prior in-
fection or colonization with antibiotic resistant organisms,
long-term care residence, hospitalizations and antibiotic
use within the past 90 days, and duration of hospital stay
prior to infection onset) and outcomes (post-infection
length of hospital and ICU stay, and ICU and hospital
mortality).
Deriving a weighted-incidence syndromic combined
antibiogram (WISCA)
A WISCA was calculated based on pathogens isolated
from patients with VAP, CRBSI, or either of these critical
care associated infections [5]. In contrast to usual anti-
biograms, which reflect the percent susceptibility of in-
dividual organisms to individual antibiotics, the WISCA
provides a weighted susceptibility of all organisms causing
a given infectious syndrome. The WISCA also provides
the opportunity to account for poly-microbial cultures
and multi-drug treatment regimens. We elected to study
the most common Gram-positive and Gram-negative anti-
microbial agents available on our hospital ICU formulary
and for which automated sensitivity testing is routinely
performed (ciprofloxacin, tobramycin, ceftriaxone, ceftazi-
dime, piperacillin-tazobactam, ertapenem, meropenem,
cloxacillin, vancomycin and linezolid). We also examined
all dual combinations of these agents other than those
which involved use of double beta-lactam agents or re-
dundant Gram-positive coverage. For each case of VAP or
CRBSI, we determined which of these monotherapy and
dual-therapy regimens would have provided adequate
coverage (as defined above) for the isolated pathogen(s).
The final WISCA displays the overall percentage of infec-
tion episodes that would have been adequately covered by
each monotherapy and dual-therapy regimen.
Statistical analysis
We calculated the excess percentage of adequate cover-
age that would have been achievable with each mono-
therapy and dual-therapy WISCA regimen, if it had been
used in place of the actual empiric antimicrobials used
in this retrospective cohort (at time points of 12 h, 24 h
and 48 h from culture collection). For any specific monoor dual-therapy regimen excess percentage of coverage
was calculated as follows:
Estimated excess percentage of coverage at a specific
time point = (% of infections that would have been co-
vered by that regimen if it had been selected empiri-
cally) – (Observed% adequately covered by actual empiric
selections used in retrospective cohort).
In the primary analysis, we calculated these excess per-
centages of adequate coverage for the overall cohort of
patients with critical care infection (either VAP or CRBSI)
to simulate the empiric situation when the site of infection
is unknown. We then recalculated the excess percentages
of adequate coverage separately for the VAP and CRBSI
subgroups.
Patients were dichotomized according to whether they
had received any early adequate empiric treatment (within
24 h of culture collection) or had not received any ad-
equate treatment during this time interval. A 24-h cut
point was selected as this almost always precedes the
availability of final susceptibility testing results. The base-
line characteristics and outcome measures were com-
pared among those receiving versus those not receiving
adequate treatment (chi-square test of proportions, and
Wilcoxon rank sum test for continuous variables). In sen-
sitivity analyses, the impact of early adequate treatment
on hospital mortality was also compared amongst VAP
and CRBSI subgroups, and by applying variations in the
definition of time to adequate treatment (12-h, 24-h, 48-h,
and 72-h cut points). If we detected a reduction in mor-
tality with early adequate treatment, we planned to ex-
trapolate the potential mortality reduction achievable with
various WISCA regimens that offered greater adequate
empiric coverage rates than that achieved with usual care
in this retrospective cohort: relative risk reduction with
adequate treatment × (% excess coverage with WISCA
regimen). We also calculated the percentage of adequate
coverage offered by the subset of dual-therapy regimens
that would have been considered concordant with the
Canadian VAP treatment guidelines [9] or the Infectious
Diseases Society of America (IDSA) CRBSI management
guidelines [10].
Sample size calculation
With our expected available sample of approximately
150 patients with critical care infections, we calculated
that we would be able to estimate the proportion of
those receiving adequate therapy in the setting of usual
care with a precision of ± 6% (with alpha 0.05, 95%
confidence level, estimated true proportion of 50%).
Similarly, we would be able to estimate the proportion
of adequate coverage offered by each mono or dual-
therapy WISCA regimen with a precision of ± 6% (and
estimates would be even more precise if true propor-
tions were >50%). The impact of adequate treatment on
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we would only have adequate power to detect a 25% ab-
solute risk reduction in this outcome (assuming 80% re-
ceived adequate treatment, baseline mortality of 40%,
power ≥80%, and alpha 0.05).Results
During the 3-year study period, 163 critical care infec-
tions were identified, including 107 culture-positive
cases of VAP and 56 CRBSI episodes.Receipt of adequate empiric antibiotic therapy
Figure 1 highlights the time from culture collection to
the receipt of adequate empiric antibiotics in critically ill
patients with VAP or CRBSI. At 12 h following culture
collection, approximately one third (35%) of patients had
received adequate antibiotic coverage to which the iso-
lated pathogen(s) were all susceptible; by 24 h about half
(52%) had received adequate antibiotics; by 48 h three-
quarters (75%) had received adequate antibiotics; and
only by 96 hours had this cumulative percentage in-
creased to 90%.Figure 1 Time to first adequate antimicrobial treatment for critical ca
patients with ventilator-associated pneumonia or catheter-related bloodstre
function of time from index microbiology specimen collection.Baseline characteristics of patients receiving or not
receiving early adequate antibiotic treatment
The baseline characteristics were similar among critically
ill patients receiving early adequate treatment within the
first 24 h (n = 84) versus those not receiving early ad-
equate treatment (n = 79) (Table 1). Those not receiving
early adequate treatment had longer lengths of stay prior
to infection (12 (7 to 47) days versus 10 (15 to 16), P =
0.03). Those not receiving adequate treatment were also
older, but this difference was not statistically significant
(64.1 (IQR 46 to 76) versus 56 (36 to 75 years), P = 0.09).
Otherwise, there were no significant differences in pa-
tient demographics, comorbidities, severity of illness, or
culprit pathogens (Table 1).
Outcomes associated with receipt of early adequate
treatment among patients with critical care infections
Hospital survival was similar among patients receiving
adequate treatment within 24 h (60/84, 71%) versus those
that did not receive this early adequate treatment (55/79,
70%) (P = 0.86) (Table 2). Early administration of adequate
antibiotic therapy was not associated with ICU survival,
hospital or ICU length of stay, or length of mechan-
ical ventilation or pressor use (Table 2). In a sensitivityre infection. The gray bars represent the cumulative percentage of
am infection receiving adequate empiric antimicrobial treatment as a
Table 1 Characteristics of patients with critical care
infections receiving versus not receiving adequate









24 h (n = 79)
P-value
Age, years, median (IQR) 56 (36 to 75) 64.13 (46.25 to 76) 0.09
Male sex, n (%) 63 (75%) 57 (72%) 0.72
Admission source, n (%)
Emergency Room 31 (37%) 25 (32%) 0.51
Ward 14 (17%) 21 (27%) 0.13
Operating Room 17 (20%) 11 (14%) 0.31
Step-up 6 (7%) 8 (10%) 0.58
Other 16 (19%) 14 (18%) 0.84
ICU Type, n (%)
Medical 28 (33%) 25 (32%) 0.87
Surgical 0 (0%) 1 (1.3%) 0.48
Trauma 2 (2%) 5 (6%) 0.27
Burns 9 (11%) 7 (8.7%) 0.79
Neurosurgical 36 (43%) 30 (38%) 0.63
Cardiac 9 (11%) 11 (14%) 0.64
ICU level, n (%)
Level 3 84 (100%) 79 (100%) 1.00
Comorbidities, n (%) 66 (78.6%) 62 (78.5%) 1.00
Heart disease 25 (30%) 16 (20%) 0.21
Peripheral vascular 9 (10.8%) 6 (8%) 0.59
Diabetes 16 (19%) 17 (21%) 0.70
Renal disease/dialysis 13 (15.5%) 10(13%) 0.66
Hypertension 27 (32%) 29 (36%) 0.62
COPD/asthma 12 (14%) 6 (8%) 0.22
Lung disease 7 (8.3%) 11 (14%) 0.32
Gastrointestinal disease 10 (12%) 15 (19%) 0.28
Liver disease 2 (2.4%) 6 (8%) 0.16
Neurological disease 14 (16.7%) 15 (19%) 0.84
Solid organ cancer 13(15.5%) 12 (15%) 1.00
Leukemia/lymphoma 3 (11.1%) 3 (4%) 1.00
Chemotherapy/
radiation
4 (15.5%) 8 (10%) 0.24
Surgery 10 (12%) 18 (23%) 0.10
Infection 2(2.4%) 7 (9%) 0.09
Multi organ dysfunction
score, median (IQR)
4 (2 to 6.2) 5 (3 to 6.5) 0.76
Organisms, n (%)
Mono-microbial 59 (70%) 58 (73.4%) 0.73
Poly-microbial 25 (30%) 21 (26.6%) 0.73
Table 1 Characteristics of patients with critical care
infections receiving versus not receiving adequate
treatment within 24 hours (Continued)
Frequent organisms, n (%)
Streptococcus pneumoniae 3 (3.6%) 8 (10%) 0.12
Staphylococcus aureus 19 (23%) 17 (21.5%) 1.00
Serratia marcescens 2 (2.4%) 3 (4%) 0.67
Pseudomonas aeruginosa 22 (27%) 12 (15%) 0.12
Klebsiella pneumonia 5 (6%) 9 (11.5%) 0.27
Klebsiella oxytoca 5 (6%) 2 (2.5%) 0.44
Haemophilus influenzae 10 (12%) 5 (6.3%) 0.28
Escherichia coli 8 (9.5%) 1 (1.4%) 0.03
Enterococcus faecalis 3 (3.6%) 5 (6.3%) 0.49
Enterobacter cloacae 3 (3.6%) 5 (6.3%) 0.49
Enterobacter aerogenes 4 (4.8%) 5 (6.3%) 0.74
Coagualse-negative
staphylococci
7 (8.3%) 14 (17.7%) 0.10
Citrobacter koseri 5 (6%) 0 (0%) 0.06





10 (5–16) Days 12 (7 to 46.5) 0.03
Previous antibiotic use
in the past 90 days
before hospital
admission, n (%)
7 (8.4%) 8 (10%) 0.79
Previous hospital visit in
the past 90 days before
hospital admission, n (%)
13 (15.5%) 13 (16.5%) 1.00
COPD, chronic obstructive pulmonary disease.
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time to adequate antibiotics (using time cut offs of 12 h,
24 h, 48 h and 72 h). At none of these cut-points did we
detect a statistically significant association between ad-
equate treatment and mortality (data not shown). A multi-
variate analysis adjusting for patient and pathogen factors
did not detect an association of early adequate treatment
and mortality (data not shown).Potential improvement in time to adequate empiric
antibiotic coverage for critical care infections with the use
of WISCAs
A WISCA was calculated to determine the percent co-
verage that would have been provided by common mo-
notherapy or dual-combination anti-microbial regimens
for critical care infections (Table 3). We also estimated
the potential excess coverage achievable by these WISCA
regimens in comparison to the antibiotic regimens actu-
ally administered to the retrospective cohort of critically
ill patients.
Table 2 Outcomes of patients with critical care infections receiving vs not receiving early adequate treatment within
24 hours
Outcomes Patients receiving early adequate
treatment within 24 h (n = 84)
Patients not receiving early adequate
treatment within 24 h (n = 79)
P-Value
Hospital survival, n (%) 60 (71%) 55 (70%) 0.86
ICU survival, n (%) 66 (79%) 63 (80%) 1.00
Hospital length of stay, days, median (IQR) 57 (31 to 92) 55 (34.25 to 128.75) 0.25
ICU length of stay, days, median (IQR) 23 (15 to 46) 28.5 (16.25 to 47.75) 0.62
Post infection hospital, days, median (IQR) 36 (18 to 69) 39 (17.5 to 80) 0.99
Length of mechanical ventilation, days, median (IQR) 18 (10 to 37) 17 (11 to 38.25) 0.78
Length of pressor use, days, median (IQR) 5 (0 to 20) 5 (0 to 27) 0.96
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have provided >80% adequate coverage for both VAP
and CRBSI. Meropenem would have offered the greatest
degree of adequate coverage (74%), followed by ciproflo-
xacin (67%) and piperacillin-tazobactam (63%). By 24 h,
most monotherapy WISCA regimens provided less ad-
equate coverage than that achieved in the retrospective
cohort. However, many dual-antibiotic WISCA regimens
would have provided >80% adequate coverage (particu-
larly when a Gram-negative agent was administered to-
gether with vancomycin), and a few even afforded >90%
adequate coverage. At 24 h, all combinations still offered
a greater probability of adequate coverage than that
obtained in the retrospective cohort. There was no ex-
cess coverage provided by the monotherapy regimens at
48 h, but there was some excess adequate coverage for
many dual-antimicrobial regimens at this late time point
(Table 3).
Similar WISCAs were derived separately for the VAP
and CRBSI subgroups (Tables 4 and 5). In these sub-
group analyses, there were still no monotherapy WISCA
regimens that offered >85% adequate antibiotic coverage;
in fact, for CRBSI, there were no monotherapy regimens
that offered >60% adequate coverage. In contrast, a grea-
ter number of dual-therapy regimens afforded >90% ad-
equate coverage for either the VAP or CRBSI sub-groups.
Dual combination regimens involving two Gram-negative
agents maximized the percentage of adequate antibiotic
coverage for VAP, while those involving vancomycin plus
an agent with broad Gram-negative coverage maximized
excess antibiotic coverage for CRBSI.
Among the VAP WISCA dual-therapy regimens we
studied, 6 of 20 would be considered concordant with the
Canadian VAP treatment guidelines (Table 4 footnote).
These 6 regimens offered an average rate of adequate
coverage of 89%, but this ranged from a minimum of 74%
for ceftazidime/tobramycin to a maximum of 95% ave-
rage coverage for piperacillin-tazobactam/ciprofloxacin.
Among the 14 non-guideline concordant dual-therapy
regimens studied, the average rate of adequate coverage
for VAP was 87%, and many offered rates of adequatecoverage similar to the guideline concordant regimens
(Table 4). Among, the CRBSI WISCA dual-therapy regi-
mens we studied, 3 of 20 would be considered concordant
with IDSA CRBSI treatment guidelines (Table 5 footnote).
These three regimens offered the highest rates of adequate
coverage (93% to 95%), and only one non-guideline con-
cordant regimen (vancomycin/ciprofloxacin) offered as
high a likelihood of adequate coverage (93%) (Table 4).
Discussion
In this study we have demonstrated the generation of a
WISCA as a tool to predict the likelihood of adequate
empiric antimicrobial coverage for patients with critical
care infections. The WISCA helped illuminate the poor
likelihood of coverage by all empiric monotherapy re-
gimens for VAP or CRBSI, while revealing a variety of
dual-therapy regimens offering high probabilities of ad-
equate coverage for either or both of these infectious
foci. Many of the dual-combination therapies that would
have been recommended by WISCA-guided data offer a
much higher degree of adequate antibiotic coverage than
that achieved by 12 h, 24 h, and even 48 h in our retro-
spective patient cohort, and so could potentially de-
crease time to adequate antimicrobial treatment in this
vulnerable patient population. However, we detected no
association between timing of adequate treatment and
patient outcomes in our ICU, and so we were unable to
estimate the potential impact of WISCA use on length
of stay and mortality among patients with these critical
care infections.
The low rates of adequate empiric coverage in our co-
hort (only 1/2 of patients by 24 h and only 3/4 of pa-
tients by 48 h) are in line with the findings of previous
investigations of VAP treatment [2,3] These low rates of
coverage are a function of the high rates of antimicrobial
resistant pathogens in North America, particularly within
the confines of the ICU [11,12]. ICU antimicrobial resist-
ance surveillance studies in Canada [12] and the US [11]
report high percentages of antimicrobial resistance, but
like traditional hospital antibiograms they display these
proportions for individual bug-drug combinations (for
Table 3 Potential improvement in adequacy of empiric
coverage for patients with critical care infections at 12,
24, and 48 hours using WISCA empiric regimens












12 h 24 h 48 h
Monotherapy
Ciprofloxacin 110 (67%) +30% +16% −8%
Tobramycin 75 (46%) +9% −5% −29%
Ceftriaxone 77 (47%) +10% −4% −28%
Ceftazidime 77 (47%) +10% −4% −28%
Pip.-Tazo. 103 (63%) +26% +12% −12%
Ertapenem 93 (57%) +20% +6% −18%
Meropenem 121 (74%) +37% +23% −3%
Cloxacillin 30 (18%) −19% −33% −57%
Vancomycin 67 (41%) +5% −10% −34%
Linezolid 68 (42%) +6% −9% −33%
Dual combination
therapy
Meropenem + Vancomycin 152 (93%) +56% +42% +18%
Ertapenem + Vancomycin 127 (78%) +41% +27% +3%
Pip.-Tazo. + Vancomycin 144 (88%) +51% +37% +13%
Ceftazidime + Vancomycin 141 (87%) +50% +36% +12%
Ceftriaxone + Vancomycin 117 (72%) +35% +21% −3%
Ciprofloxacin + Vancomycin 151 (93%) +56% +42% +18%
Tobramycin + Vancomycin 151 (93%) +56% +42% +18%
Ciprofloxacin + Cloxacillin 134 (82%) +45% +31% +7%
Tobramycin + Cloxacillin 116 (71%) +34% +20% −4%
Meropenem + Tobramycin 126 (77%) +40% +26% +2%
Ertapenem + Tobramycin 126 (77%) +40% +26% +2%
Pip.-Tazo. + Tobramycin 128 (79%) +42% +28% +4%
Ceftazidime + Tobramycin 102 (63%) +26% +12% −12%
Ceftriaxone + Tobramycin 115 (71%) +34% +20% −4%
Meropenem + Ciprofloxacin 143 (88%) +51% +37% +13%
Ertapenem + Ciprofloxacin 143 (88%) +51% +37% +13%
Pip.-Tazo. + Ciprofloxacin 144 (88%) +51% +37% +13%
Ceftazidime + Ciprofloxacin 137 (84%) +47% +33% +9%
Ceftriaxone + Ciprofloxacin 136 (83%) +46% +32% +8%
Ciprofloxacin + Tobramycin 135 (82%) +45% +31% +7%
WISCA, weighted incidence syndromic combined antibiogram; VAP, ventilator-
associated pneumonia; CRBSI, catheter-related bloodstream infection;
Pip.-Tazo., piperacillin-tazobactam.
Table 4 Potential improvement in adequacy of empiric
coverage for ventilator-associated pneumonia at 12 h,
24 h, and 48 h using WISCA empiric regimens












12 h 24 h 48 h
Monotherapy
Ciprofloxacin 82 (77%) +37% +24% 0%
Tobramycin 55 (51%) +11% −3% −26%
Ceftriaxone 59 (55%) +15% +2% −22%
Ceftazidime 58 (54%) +14% +1% −23%
Pip.-Tazo. 74 (69%) +29% +16% −8%
Ertapenem 70 (65%) +25% +12% −12%
Meropenem 91 (85%) +45% +32% +8%
Cloxacillin 29 (27%) −13% −26% −50%
Vancomycin 36 (34%) −6% −19% −43%
Linezolid 36 (34%) −6% −19% −43%
Dual combination
therapy
Meropenem + Vancomycin 99 (93%) +53% +40% +15%
Ertapenem + Vancomycin 77 (72%) +32% +19% −5%
Pip.-Tazo. + Vancomycin 92 (86%) +46% +33% +9%
Ceftazidime + Vancomycin 89 (83%) +43% +30% +6%
Ceftriaxone + Vancomycin 68 (64%) +24% +11% −13%
Ciprofloxacin + Vancomycin 101 (94%) +54% +41% +17%
Tobramycin + Vancomycin 99 (93%) +53% +40% +16%
Ciprofloxacin + Cloxacillin 99 (93%) +53% +40% +16%
Tobramycin + Cloxacillin 93 (87%) +47% +34% +10%
Meropenem + Tobramycin* 94 (88%) +48% +35% +11%
Ertapenem + Tobramycin 93(87%) +47% +34% +10%
Pip.-Tazo. + Tobramycin* 96 (90%) +50% +37% +13%
Ceftazidime + Tobramycin* 79 (74%) +14% +21% −3%
Ceftriaxone + Tobramycin 92 (86%) +46% +33% +9%
Meropenem+ Ciprofloxacin* 101 (94%) +54% +41% +17%
Ertapenem + Ciprofloxacin 100 (93%) +53% +40% +16%
Pip.-Tazo. + Ciprofloxacin* 102 (95%) +55% +42% +18%
Ceftazidime + Ciprofloxacin* 100 (93%) +53% +40% +16%
Ceftriaxone + Ciprofloxacin 99 (93%) +53% +40% +16%
Ciprofloxacin + Tobramycin 99 (93%) +53% +40% +16%
WISCA, weighted incidence syndromic combined antibiogram; VAP, ventilator-
associated pneumonia; CRBSI, catheter-related bloodstream infection;
Pip.-Tazo., piperacillin-tazobactam. *Regimens that would be considered
concordant with Canadian VAP treatment guidelines [9].
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found to be resistant to ciprofloxacin in 2009 to 2010)
[11]. These national, regional or hospital-specific antibio-
gram reports can alert clinicians to the general problem ofantimicrobial resistance, but do not answer the immediate
clinical question for their patients; namely, what is the
likelihood of adequate coverage that will be achieved with
Table 5 Potential improvement in adequacy of empiric
coverage for catheter-related bloodstream infection at
12 h, 24 h, and 48 h using WISCA empiric regimens












12 h 24 h 48 h
Monotherapy
Ciprofloxacin 28 (50%) +20% +2% −21%
Tobramycin 20 (36%) +6% −12% −35%
Ceftriaxone 18 (32%) +2% −16% −39%
Ceftazidime 19 (34%) +4% −13% −37%
Pip.-tazo. 29 (52%) +22% +4% −19%
Ertapenem 23 (41%) +11% −7% −30%
Meropenem 30 (54%) +24% +6% −17%
Cloxacillin 1 (2%) −28% −47% −69%
Vancomycin 31 (55%) +25% +7% −16%
Linezolid 32 (57%) +27% +9% −14%
Dual-combination
therapy
Meropenem + Vancomycin* 53 (95%) +65% +47% +24%
Ertapenem + Vancomycin 50 (89%) +59% +42% +18%
Pip.-Tazo. + Vancomycin* 52 (93%) +63% +45% +22%
Ceftazidime + Vancomycin* 52 (93%) +63% +45% +22%
Ceftriaxone + Vancomycin 49 (88%) +58% +40% +17%
Ciprofloxacin + Vancomycin 52 (93%) +63% +45% +22%
Tobramycin + Vancomycin 50 (89%) +59% +41% +18%
Ciprofloxacin + Cloxacillin 35 (63%) +33% +15% −8%
Tobramycin + Cloxacillin 23 (41%) +11% −7% −30%
Meropenem + Tobramycin 32 (57%) +27% +9% −14%
Ertapenem + Tobramycin 33 (59%) +29% +11% −12%
Pip.-Tazo. + Tobramycin 32 (57%) +27% +9% −14%
Ceftazidime + Tobramycin 23 (41%) +11% −7% −30%
Ceftriaxone + Tobramycin 23 (41%) +11% −7% −30%
Meropenem + Ciprofloxacin 42 (75%) +45% +27% +4%
Ertapenem + Ciprofloxacin 43 (77%) +47% +29% +6%
Pip.-Tazo. + Ciprofloxacin 42 (75%) +45% +27% +4%
Ceftazidime + Ciprofloxacin 37 (66%) +36% +18% −5%
Ceftriaxone + Ciprofloxacin 37 (66%) +36% +18% −5%
Ciprofloxacin + Tobramycin 36 (64%) +34% +16% −7%
WISCA, weighted incidence syndromic combined antibiogram; VAP, ventilator-
associated pneumonia; CRBSI, catheter-related bloodstream infection; Pip.-Tazo.,
piperacillin-tazobactam. *Regimens that would be considered concordant with
Infectious Diseases Society of America CRBSI treatment guidelines.
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with clinical infection. By displaying the susceptibility
rates by syndrome, rather than pathogen, the WISCA hasthe potential to increase adequate antimicrobial use. In
our population, there were WISCA-guided regimens that
would have offered an excess of up to +42% more patients
receiving adequate coverage by 24 h compared to current
practice.
According to WISCA calculations, the regimens with
the highest likelihood of adequate coverage for CRBSI
were the same as those that would be considered concord-
ant with IDSA CRBSI treatment guidelines by containing
both vancomycin and an anti-Pseudomonal beta-lactam
[10]. Therefore, it is not clear whether locally derived
WISCA data would improve upon the likelihood of ad-
equate CRBSI coverage, if practice was already concordant
with these guidelines. In contrast, WISCA calculations for
VAP indicated that many non-guideline concordant dual-
therapy regimens were just as likely as guideline con-
cordant dual-therapy regimens to provide adequate VAP
coverage [9]. Therefore, WISCA data has the potential to
expand the range of empiric treatment options for VAP
patients based on local antimicrobial resistance profiles.
Our study was unable to confirm the clinical benefit of
early adequate antibiotic treatment, that has been docu-
mented in previous studies of infection in critically ill
patients [1-3,13-15]. Although the importance of early
adequate treatment is controversial [16-18], we believe
that the lack of association with mortality in our study
related to insufficient statistical power. The clinical tra-
jectory of only a subset of patients with critical care
infection would be expected to benefit from early ad-
equate treatment. Many patients with infection-triggered
systemic inflammation will continue to deteriorate even
once the trigger has been treated; whereas other non-
hypotensive patients may be stable enough to tolerate sub-
stantial delays in treatment [19], A recent meta-analysis
has determined that the attributable mortality of VAP is
only 13%, which represents a low ceiling on the potential
benefit of any therapeutic intervention including timely
antibiotics [20]. Based on the observed 30% mortality in
our population, we would have required 332 patients to
detect such a maximal 13% absolute mortality reduction;
to detect a more realistic mortality reduction of 5% a pro-
spective study would need to enroll approximately 2,500
patients.
Even though infections were prospectively defined using
stringent surveillance definitions, over-diagnosis of VAP
likely remained important given the lack of an effective
gold standard test for this condition, the notoriously low
specificity of clinical and microbiology criteria, and the
pervasiveness of competing diagnoses such as acute re-
spiratory distress syndrome and congestive heart failure
[21-25]. Inclusion of patients without VAP may have
diluted any signal of benefit of early antibiotic treat-
ment. Bias-by-indication may also have masked a bene-
fit of adequate treatment, given that broader treatment
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sicker patients; although we accounted for important
measurable confounders, we cannot rule out residual
confounding in this observational study design. Our
study was also limited by the use of single-center data,
such that the types of patients and prevalence of an-
timicrobial resistance may differ from those in other
centers, but we have demonstrated how WISCAs could
easily be generated by other ICUs based on their local
ecology. By definition, WISCA values and adequate
treatment definitions are derived from culture-positive
patients, so we cannot necessarily extrapolate our find-
ings to culture-negative infections in the ICU. Additio-
nally, the predominant use of relatively non-specific
endotracheal tube specimens means that the culprit or-
ganism(s), and in turn the adequacy of treatment, may
have been mislabeled in some VAP cases. We defined
time to adequate antibiotics from the time of culture
collection, whereas time from onset of hypotension or
organ failure may be more closely tied to important pa-
tient outcomes [1]. Lastly, the WISCA does not quantify
the hazards of broad-spectrum antimicrobial use, which
must also be weighed into empiric antibiotic decisions.
Conclusions
In summary, our study demonstrated that a WISCA can
be derived for patients with ICU-acquired infections,
and that WISCA-derived empiric antimicrobial regimens
have the potential to reduce the time to initiation of ad-
equate treatment. Prospective research is needed to con-
firm whether actual provision of WISCA antimicrobial
prescribing-aids to ICU clinicians are associated with
improvements in timely and rational antimicrobial treat-
ment, and in turn whether this can lead to meaning-
ful improvements in clinical outcomes for critical care
patients.
Key messages
 In contrast to traditional antibiograms, WISCAs
display the likelihood of coverage for a specific
infectious syndrome (rather than individual
pathogens), and also take into account the potential
for poly-microbial infections and the use of
multi-drug regimens
 WISCAs can be constructed based on local ecology
data for common ICU infections such as VAP or
CRBSI
 In this retrospective cohort study, only 1/3 of
patients received adequate coverage by 12 h, 1/2 of
patients 24 h and only 3/4 of patients by 48 h from
culture collection
 Use of WISCA-guided double antibiotic therapy
regimens could potentially have resulted in adequatecoverage rates +56%, +42% and +18% higher than
current care at 12-h, 24-h and 480 h time points
 Prospective research is needed to determine
whether actual provision of WISCA antimicrobial
prescribing-aids to ICU clinicians are associated
with improvements in timely and rational
antimicrobial treatment
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